Skip to main content
. Author manuscript; available in PMC: 2020 Jun 26.
Published in final edited form as: Diagnosis (Berl). 2019 Jun 26;6(2):157–163. doi: 10.1515/dx-2018-0066

Table 3:

Multivariable linear regression model predicting the number of tests ordered for a fever.

Variable Estimate (SE) p-Value
Hospital 0.02
 Community Reference
 Academic 1.10 (0.46)
Age 0.00 (0.01) 0.68
Charlson comorbidity index 0.08 (0.05) 0.11
Organ transplant recipient −0.49 (0.51) 0.34
Immunosuppressed statusa 0.51
 None Reference
 Low 0.43 (0.49)
 High 0.30 (0.29)
Met at least two of four SIRS criteriab 0.30 (0.30) 0.33
Met at least two qSOFA criteriac 0.41 (0.68) 0.55
Last time blood cultures drawn <0.001
 Never Reference
 < 24 −2.05 (0.46)
 24–48 h −1.82 (0.47)
 49–72 h −0.77 (0.53)
 >72 −0.47 (0.52)
Resident level of training 0.04
 PGY-1 Reference
 PGY-2 1.11 (0.42)
 PGY-3 0.92 (0.64)
Note written by cross-cover resident 1.35 (0.86) 0.12
Indication that cross-cover resident saw patient 1.42 (0.56) 0.02
Patient transferred to higher level of care 4.03 (1.06) <0.001
Sign-out instructed to perform an FFWU 1.48 (0.27) <0.001

FFWU, full fever work-up; PGY, post-graduate year; qSOFA, quick sepsis-related organ failure assessment; SE, standard error; SIRS, systemic inflammatory response syndrome.

a

Patients with high-level immunosuppression included those with combined primary immunodeficiency disorder, receiving cancer chemotherapy, within 2 months after solid organ transplantation, with HIV infection and a CD4 T-lymphocyte count < 200 cells/mm3, receiving daily corticosteroid therapy with a dose ≥ 20 mg of prednisone or equivalent for ≥ 14 days, or receiving certain biologic immune modulators, including tumor necrosis factor-α (TNF-α) blockers or rituximab. Patients with low-level immunosuppression include those with asymptomatic HIV and a CD4 T-lymphocyte count of 200–499 cells/mm3, receiving a lower daily dose of systemic corticosteroid than for high-level immunosuppression for ≥14 days or receiving alternate-day corticosteroid therapy or receiving methotrexate ≤ 0.4 mg/kg/week, azathioprine ≤ 3 mg/kg/day, or 6-mercaptopurine ≤ 1.5 mg/kg/day [13].

b

SIRS consists of temperature > 38° C or < 36° C, heart rate > 90/min, respiratory rate > 20/min or PaCO2 < 32 mmHg, and white blood cell count > 12,000/mm3 or < 4000/mm3 or > 10% immature bands.

c

qSOFA includes a respiratory rate of 22/min or greater, altered mentation, or systolic blood pressures of 100 mmHg or less. Patients meeting at least two of these criteria are more likely to have poor outcomes [15].